Bioventus BVS Weighted Average Exercise Price of Exercisable Options

Weighted Average Exercise Price of Exercisable Options at other companies

Globus MedicalGMED

——

SI-BONE, Inc.SIBN

——

Other financials

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

See full

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's weighted average exercise price of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bioventus's weighted average exercise price of exercisable options?: Bioventus (BVS) reported weighted average exercise price of exercisable options of $8.94 in Q1 2026.
How has Bioventus's weighted average exercise price of exercisable options changed year-over-year?: Bioventus's weighted average exercise price of exercisable options decreased by 8.2% year-over-year, from $9.74 to $8.94.